Member Info for miavoce

Agreed scinv_temp

The fact that Genmab came back for a 2nd Glymab demonstrates that they are very happy with the first one. Just a matter of time till the phase I starts.

Final SCIB1 scan should be next week (possibly may already have happen). We are on the cusp of news flow.

Violindog - I'll stick my neck out and go for 2025 :-)

Scinv_temp it won't be this month as the final 26 week scan will only take place at the end of this moth (based on the final recruit being onboarded towards the end of Nov 2024).

How on earth are you linking the date of the SCIB1 results to the performance of IM SCIB1+ ? I can see that you would would make such a statement in order to continue your highly negative stance on SCLP, but I can't see any logic to your statement.

OK, let's have your predictions for when the SCIB1 results RNS will land.

I'm going for Tuesday 17th June.

Rest I peace mate.

Great to see Scancell selected for the shortlist and also good to see that they are using more avenues to raise awareness of what they are achieving.

Lots of positive vibes coming out of the company. iSCIB1+ must be looking good.

A lot of people seem not to understand the basic concept here i.e the CPI (such as Nivolumab) let's the immune system access the cancer, and SCIB / MODI turbo charge the immune system so that it has the power to overcome the cancer. A totally synergistic relationship. The fact the delivery of the CPI has changed from IV drip to injection in irrelevant.

The use of Avidimab has a very clear and important purpose. Scinv_temp is talking nonsense.

This is what Avidimab is doing. The AvidiMab modification to the Fc region of the antibody produced by Scancell's iSCIB1+ vaccine strengthens the interaction with Fc receptors on dendritic cells and other antigen-presenting cells. This enhanced binding increases the avidity and efficiency of antigen uptake, processing, and presentation by dendritic cells, thereby amplifying the activation of T-cell-mediated immune responses against melanoma-specific antigens (such as TRP-2 and gp100).

As a result of using Avidimab the mAb has longer 'on-time' with the dendritic cells and primes them more effectively. When the dendritic cells reach the lymph nodes they then stimulate the T-Cell much more effectively creating much higher avidity T-Cells.

Hopefully the benefit of applying Avidimab will be very apparent when we see the cohort 3 results in a matter of weeks.

Why not just create a login DaveDaveDave, it is very easy ? The presentation isn't hidden. Also the video of the IM session is on the Scancell website. Nothing is being hidden, quite the opposite.

Hi DaveDaveDave, there was a link on the Investor Meet site to download the presentation.

Yes, Scinv_temp is correct. Product decision mid year, delivery mechanism (IM vs ID) end of year. This is what Phil said.

Here you go Dave, I've put it in dropbox for anybody that wants the pdf

https://www.dropbox.com/scl/fi/t6px76ge4ddkr06tss06v/Scancell-Presentation.pdf?rlkey=vkqsb3d7nl4tt3r6ewf9qwt30&st=wv3qgloc&dl=0

Thanks Burble, I had similar thoughts but wasn't sure.

One thing puzzling me.

The forecast market size for unresectable is 70k patients / $4.2bn i.e. $60k per patient

The forecast market size for Neoadjuvant/Adjuvant is 250k patients / $6bn i.e. $24k per patient

Why does the Neoadjuvant/Adjuvant treatment generate a lot less income per patient ?

It wouldn't surprise me if Scancell were to spin off the Glymabs into a separate company and raise funds for it as part of it's listing. Currently the mAbs are being ascribed little or no value (as illustrated by our current SP) as they are playing second fiddle to the cancer vaccines but housing them in a separate company should help their valuation.

I've submitted the following questions. Let's see what gets answered.

Question 1 : The partnering of the NHS's strategic CVLP initiative with a (currently) very small UK biotech, when they have so far focused on major biotechs, strikes me as unusual. What persuaded CVLP that supporting the SCOPE trial cohort 4 would be a good proposition for them ?

Question 2 : The CEO recently stated that he is determined to find a way to move forward with in-house development of the Glymabs. How will this be funded ?

Question 3 : Is Avidimab attracting any industry interest as yet ? Does the company anticipate that the iSCIB1+ data might help drive the wider commercialisation of Avidimab ?

Question 4 : Is the company still anticipating the near term commencement of a Phase 1 by Genmab with respect to either of the licensed Glymabs ?

Question 5 ; Has the partnership with CVLP enhanced the industry interest in partnering SCIB1 ?

Question 6 : Can we expect interim updates on iSCIB1+ performance similar to the interim updates provided in relation to SCIB1 performance ?

Oops, stand down. Looks like he has posted something relating to when CRUK had a partnership with Scancell a few years ago. The wording in what he posted is very similar to this article from 2019.

https://www.drugtargetreview.com/news/44154/update-novel-cancer-immunotherapy/